Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOULDER, Colo., May 30, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2013 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)
Event: | Jefferies 2013 Global Healthcare Conference |
Presenter: | Ron Squarer, Chief Executive Officer |
Date: | Tuesday, June 4, 2013 |
Time: | 10:30 a.m. Eastern Time |
Webcast: |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted smallmolecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS- and BRAF-mutant melanoma in 2013. In addition, Array expects to begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013. AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib (an Arrayinvented drug) in non-small cell lung cancer and thyroid cancer during the second half of 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array’s wholly-owned drugs, ARRY520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
303-386-1193 | |
SOURCE Array BioPharma
Help employers find you! Check out all the jobs and post your resume.
